Showing posts with label Third World. Show all posts
Showing posts with label Third World. Show all posts

Monday, April 12, 2021

Teminology: Vaccine apartheid

Copyright © Françoise Herrmann

As the COVID-19 vaccination campaign picks up speed in the US, with a record 3 to 4 million vaccinations per day, issues of global access to COVID-19 vaccines and of vaccination campaign equity have arisen. Vaccine apartheid is the term that has been coined in reference to global inequity in vaccine distribution, and corollary access to COVID-19 vaccination. By way of comparison, for example, according to Médecins sans frontières/Doctors Without Borders, a country like Iraq has received 360,000 doses of the Astra Zaneca vaccine for a population of 40 million (Ebeid, O., 2021). 

According to the British scientific research journal Nature, the following threefold issue is at the root of the emerging global inequity of COVID-19 vaccine distribution: 1>COVID-19 vaccine production capacity, 2> the purchasing power of rich nations who have pre-ordered vaccines, and 3> patenting rights, which exclude the transfer of technologies beyond those few companies owners of the intellectual property (IP) rights, already producing the vaccines at full capacity, primarily in the West, China and Russia. In other words, patenting rights perceived as obstructing the supply of COVID-19 technologies, in response to an extremely urgent demand. In sum, whatever vaccine production exists, it is already largely earmarked for those (rich) countries, who have pre-ordered, compounded by the fact that patenting rights prevent production from being distributed elsewhere, among other facilities, for example in medium–income nations. A production that would cover local populations, and the population of the poorest nations, without facilities or any purchasing power. 

Thus, medium-income, and poor nations, not only have to wait for vaccines (perhaps till 2022 or 2023), they have to wait far longer than necessary, because production is prevented from happening elsewhere. In terms of numbers, poorer nations, making up to 80% of the world population, currently have access to less than one-third of the available COVID-19 vaccines (Nature Editorial, 2021). The World Trade Organization (WTO), is thus currently under the pressure of an India and South Africa-led coalition of 100 nations, with civil society support, demanding that intellectual property rights for COVID-19 vaccine technologies be temporarily lifted, at least until the pandemic is under control, so that production can be set up elsewhere than at the few facilities of the western world for the Pfizer, Moderna, Johnson & Johnson, and Astra Zaneca vaccines, as well as for the Sinopharm vaccine in  China and the Sputnik V vaccine in Russia. (The People's VaccineGlobal Justice now).

Such a dramatic situation, oblivious of the public health interest, is not altogether unfamiliar. With hindsight from the disastrous monopoly on antiretroviral therapies (ART) within the context of the AIDS pandemic, pharmaceutical companies, such as Moderna, have indeed waived enforcing their patenting rights against others making the COVID-19 vaccine till the end of the pandemic, and will grant licensing rights for the mRNA technology post-pandemic. A pledge that technically lifts the monopoly on pricing conferred by patenting rights, promoting the development of a new vaccination paradigm, while still falling short on the possibility of transferring vaccine know-how and manufacturing to the Third World, during the pandemic (Shore, 2020). However, considering the absence of electricity for 1.5 billion people in the Third World, the Moderna vaccine is also considered an unsuitable candidate vaccine for the Third World, primarily due to the low-temperature storage conditions and to the costs of a double-dose regimen (Curtis, 2020). Likewise, for the same reasons, the Pfizer vaccine is deemed even more significantly ill-suited for the Third World, considering the extreme cold storage conditions (-70 degrees Celsius) required for the costly double-dose regimen of the Pfizer vaccine (1). Thus, the small set of pharmaceutical companies, producing effective COVID-19 vaccines worldwide, and especially those deemed more suitable for the Third World  (e.g.; Astra Zaneca), are being specifically urged to live up to the spirit of solidarity that was put forward during the early phases of public funding for research and development of COVID-19 vaccine development (Ellman, 2021). An urgent request that often forcibly ends up as a desperate appeal to all rich countries and pharmaceutical companies implicated, for the purchase and donation of vaccines to poorer nations, not only in need of COVID-19 vaccines right now, but of the right vaccines (Nature Editorial, 2021).

If the obscene cruelty of an unnecessary wait for medical technologies appears to be repeating within the context of the emerging vaccine apartheid of the COVID-19 pandemic, an even greater threat is seen lurking on the horizon. According to UNAIDS Executive Director Winnie Byanyima, vaccine apartheid for the poorest countries of the world not only prevents those countries from exiting the health and economic crisis brought about by the COV-2 pandemic, on a par with the rest of the world, vaccine apartheid also puts the rest of the planet at risk, canceling the possibility of eradication. Indeed, according to Byanyami: 

"The longer the virus is allowed to continue in a context of patchy immunity, the greater the chance of mutations that could render the vaccines we have and the vaccines some people in rich countries have already received, less effective or ineffective." (Byanyima, 2021)

In other words, for all who have survived to tell the tale of the year 2020, the COVID-19 pandemic clearly illustrates global interdependency, just in case such a dynamic might have previously appeared untenable. As Democracy Now! puts it succinctly: “If one person is unprotected, we are all unprotected.” (Goodman & Moynihan, 2020), a situation that vaccine apartheid might be in the process of amplifying. 

-------------

(1) As of March 5, 2021 Rwanda is the only African country thus far with a Pfizer vaccination campaign, launched using special storage technology. Astra Zaneca, the vaccine generally known to be a more suited vaccine for the Third World, was also launched  in Rwanda (Uwiringiyimana, 2021).

References

Byanyima, W. (Feb. 18, 2021) UNAIDS -  A global vaccine apartheid is unfolding. People’s lives must come before profit. UNAIDS.   https://www.unaids.org/en/20210203_oped_guardian

Curtis, J. (Nov. 30, 2020) Coronavirus: Access to vaccines in developing countries. https://commonslibrary.parliament.uk/coronavirus-access-to-vaccines-in-developing-countries/

Ellman, T. Dr.  (Feb. 18, 2021) Southern Africa needs the right COVID-19 vaccines, at the right price – right now. Médecins sans frontiers (MSF)/Doctors Without Borders (DWB).   https://www.msf.org/msf-urges-rich-countries-share-appropriate-covid-19-vaccines-southern-africa

Ebeid, O. (March 31, 2021) Only vaccination will end the ferocious spread of COVID-19 in Iraq. Médecins sans frontiers (MSF)/Doctors Without Borders (DWB).   https://www.msf.org/iraq-only-vaccination-will-end-fast-spread-covid-19

Glenza, J. (March 31, 2021) Coronavirus: How wealthy nations are creating a vaccine apartheid. The Guardian.    https://www.theguardian.com/world/2021/mar/30/coronavirus-vaccine-distribution-global-disparity 

Global Justice Now! https://www.globaljustice.org.uk

Goodman, A & D. Moynihan (FEb. 25, 2021) Vaccine Apartheid: If One Person Is Unprotected, We Are All Unprotected.    https://www.democracynow.org/2021/2/25/vaccine_apartheid_if_one_person_is

O’Neill, J. (March 18, 2021) End vaccine apartheid by waiving patents and save us all from Covid-19. The Guardianhttps://www.theguardian.com/world/2021/mar/18/end-vaccine-apartheid-by-waiving-patents-and-save-us-all-from-covid-19

Shores, M. (November 2020) Breaking Down Moderna’s COVID-19 Patent Pledge: Why Did They Do It? https://www.ipwatchdog.com/2020/11/11/breaking-modernas-covid-19-patent-pledge/id=127224/

Staff (March 31, 20210 It’s time to consider a patent reprieve for COVID vaccines. Nature.   https://www.nature.com/articles/d41586-021-00863-w

Staff (March 21, 2021) Interview: Three questions on worrying COVID-19 surge in Papua New Guinea. Médecins sans frontiers (MSF)/Doctors Without Borders (DWB).   https://www.msf.org/png-health-system-verge-collapse-following-covid-19-surge An

Staff (March 25, 2021) COVID-19 support desperately needed as second wave overwhelms Yemen. Médecins sans frontiers (MSF)/Doctors Without Borders (DWB).   https://www.msf.org/covid-19-support-desperately-needed-second-wave-overwhelms-yemen

The People's Vaccinehttps://peoplesvaccine.org/ 

Thursday, March 12, 2020

Oh, patents! The InfaClip™

Copyright © Françoise Herrmann

Whether due to unsafe socio-cultural practices, inadequate access to healthcare or a combination of both, two-thirds of neonatal deaths occur in the developing world. To prevent neonatal death in the developing world, specifically due to umbilical cord infections, University of Tulane spinoff, at Novate Medical Technologies, has developed the InfaClip (formerly designated the SafeSnip).

The InfaClip is a patented invention, recited in the UN WIPO (World Intellectual Property Organization) patent, WO2012129317A1, titled Multi-component detachable jaw tools and methods of using and making same. Specifically, the InfaClip is a 3-inch, disposable, plastic obstetric device, intended to clamp, severe and disinfect the umbilical cord. The InfaClip actually consists of two identical clips, made from the same plastic injection mold, one of which breaks off, after the cord has been severed from the placenta. The clip left in place then seals the wound, protecting it from infection.

In contrast to existing obstetrical devices for clamping and severing umbilical cords, consisting within medical settings of several instruments (metal clamps and scissors, plus plastic clamp), or in non-medical settings of strings and a blade, the InfaClip offers a two-step process. The two-step process comprises 1. disengaging a hinge-locking mechanism for the purpose of unlocking the open jaws of the InfaClip to clamp/cut the cord, and  2. breaking off the InfaClip part connected to the severed cord and placenta, leaving the other half in place. The part that stays to protect the wound is also removable, without the use of any extra cutting tools,  just applying downward pressure on a disengageable lip and lever closure of the two jaws, at the opposite end of the hinge. Finally, the InfaClip grip is specifically designed to distribute the forces applied when closing the jaws, at the center of the clip, thereby facilitating severance, while protecting for against blood splatter, to prevent Hepatitis B &C and HIV contamination.

The patent recites various embodiments of this invention applied to the severance of an umbilical cord, but it is also disclosed that the scope of the invention is in fact much larger. Indeed, variations, known to persons skilled in the art, might be designed for other vascular, gastrointestinal, gynecological (e.g.; tubal ligations) or respiratory purposes, without departing from the spirit of the invention.  In this regards the detailed description of the invention also contains a detailed section on the definition of terms. For example, the patent recites the regulatory “open-ended” definitions of such terms as “comprising” and the indefinite articles “a/an”,  respectively used  within the patent to mean: “at least” and “one or more”, precisely for the purpose of construing the broadest possible claims, without limitations (unless nonsensical).

The abstract of this invention is included below together with the patent Figure 2, and a corresponding image of the separated InfaClip. The patent Figure 2 shows the two symmetrical components, Unit A and Unit B, of the InfaClip device 1, that separate after clamping/cutting of the cord. The hinge 50 brings both units together, while comprising hinge portions 52 and 54 on each unit. The Units A and B, working together as unitary jaw members, are designated 40 and 30. Figure 2 further depicts the sawtooth blades 91, 92, configured to receive one another when the jaws are closed, and the chamfered clamping surfaces, comprising working surfaces 34 and 44, on Unit B, and working surfaces 32 and 42 on Unit A, each abutting one another when the jaws are closed.
Provided is a jaw tool formed from two separable units and which includes a fastening device that attaches the two units together when the jaw tool is in use and which may automatically separate the units after the device performs its function such as clamping and/or cutting. Also provided is a jaw tool having a cutting blade wherein the contours of the device are shaped so that force is concentrated on the cutting bade when the device is closed. The jaw tool may be manufactured from a single injection molded-component that is used in duplicate to form the jaw tool. The jaw tool may be used in various applications in which it may be beneficial to simultaneously clamp and cut an object, such as various medical applications including vascular, gastrointestinal, respiratory, and placental. [Abstract WO2012129317A1]
References
Brannon, K. (2009) Student's invention aids safe childbirth. 
http://www2.tulane.edu/news/newwave/081809_safesnip.cfm
WHO - Innovation in umbilical cord severance
https://www.who.int/medical_devices/global_forum/3rd_gfmd/umbilicalcordseverance.pdf
Youtube - Infaclip™ - Novate Medical Technologies
https://www.youtube.com/watch?v=J1TSi6iMbR8

Monday, February 10, 2020

Oh, patents! Kickstart International MoneyMaker treadle pump

Copyright © Françoise Herrmann

To assist in the transition from rain-fed farming to irrigated agriculture, Kickstart International also produces a MoneyMaker treadle pump. The Kickstart International treadle MoneyMaker pump (MMP) is designed to provide a reliable way of transporting water. It is also easy to repair, low-cost and light, while remaining stiff-enough for stable operation.To pump water with a treadle pump, the user stands on the treadles, pushing one treadle after another in a reciprocal manner.

The YouTube video below shows a Kickstart International treadle MMP in operation.


In general, the reported advantages of using treadle pumps, compared to bucket irrigation, are increased income via increased crop yield, due to increased area irrigated (UNFAO, 2000)

This Kickstart International MMP invention is recited in the US patent US8770954B2, titled Human-powered irrigation pump. This patent recites an improvement on the many existing treadle pumps, since they were first developed and introduced in Bangladesh, in the 1980s (UNFAO, 2000). The inventive improvements address the specific context of African agriculture, where water is generally pumped from more distant ground sources for irrigation.

The abstract of the Kickstart treadle MMP invention is included below, together with the patent Figures 3 and 4A.  Figure 3 depicts an embodiment of the treadle MMP pump 200, where two treadles 208, 208’ are coupled to a horizontal reciprocating rocker 202, supported by a rocker pivot 212 (shown in Fig. 4A), mounted to the frame 218. The rocker 202 is mounted between the treadles 208, 208’, at a distance below the horizontal treadle pivot 214. The horizontal treadle pivot 214 enables the treadles to rotate up and down, during pumping. The treadles 208, 208’ are respectively connected to two pistons 206, 206’, each piston also connected via tensile member to the reciprocating rocker 202. Thus, the downward movement of treadle 208, pushing piston 206 down, will also bring down the reciprocating rocker 202, forcing it to rotate on the rocker pivot 212, in turn pulling up piston 206’ and its connected treadle 208’.  

The lowest and highest points of reciprocating travel for the treadles 208, 208’ are depicted in Figure 4A as distance Z, while the lowest and highest points of piston travel are depicted as distance γ. Likewise, the offset elevation of the treadle and rocker pivots 212, 214, is shown as distance x

Footplates 220 are shown at the distal end of each treadle, to minimize slipping when pumping, on both Figures 3 and 4A.
A human-powered pump assembly includes a frame and a treadle pivot attached to the frame, such that the treadle pivot defines a horizontal rotational axis. The pump assembly includes a pair of treadles coupled to the treadle pivot and a rocker pivot attached to the frame, such that the rocker pivot defines a separate horizontal rotational axis. The pump assembly includes a reciprocating rocker coupled to the rocker pivot and to the pair of treadles to constrain the motion thereof, such that the rocker pivot axis is located below the treadle pivot axis. [Abstract US8770954B2]
References
Kickstart International Inc.
UNFAO (United Nations Food & Argriculture Organization) Kay, M. & T. Brabben (Oct. 1, 2000) Treadle Pumps for Irrigation in Africa. IPTRID -  International Programme for Technology and Research in Irrigation and Drainage - Knowledge Synthesis Report.
http://www.fao.org/3/X8293E/X8293E00.htm